Duloxetine (Cymbalta®) May Exacerbate Hepatic Injury in Patients with Preexisting Liver Disease
October 8, 2009
Eli Lilly and Company has revised the duloxetine (Cymbalta®) product labeling to include new information about hepatic injury. In postmarketing, duloxetine has been associated with hepatic injury, including hepatitis and cholestatic jaundice, in patients with preexisting chronic liver disease. To reduce the risk of injury, consider avoiding duloxetine use in patients with preexisting liver disease, any hepatic insufficiency, or substantial alcohol use. For more information visit the following links:
- FDA MedWatch alert:
- Dear Health Care Professional Letter:
- Revised package insert, June 2008:
October 8, 2009; October 18, 2005; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.